SlideShare a Scribd company logo
1 of 24
Download to read offline
NON - LINEAR
PHARMACOKINETICS
1
Contents
Introduction
Definition
Saturable enzymatic elimination process
Drug elimination by capacity limited pk
Mixed drug elimination
Time dependent PK
Conclusion
References
2
LINEAR PHARMACOKINETICS
• linear kinetics : In most cases, at therapeutic doses, the change in
the amount of drug in the body or change in plasma concentration
due to ADME is directly proportional to its dose, whether single or
multiple dose. In such situations, the rate process are said to follow
first order or linear kinetics.
• Plot on semilog paper C vs t for different doses, when corrected for
dose administered, are super impossible. This is called as principle
of superposition.
• It defines the relationship between the dose & the time course of
drug concentration in the body..
3
NON LINEAR PHARMACOKINETICS2
• Synonyms: Capacity limited Kinetics, Mixed order Kinetics
(Dose Dependent Kinetics) ,Nonlinear
• Why it is known as Mixed order kinetics?
In some cases the kinetics of PK process changes from 1st
order to zero order with increase in dose or chronic
medication. So mixture of both 1st and zero order observed
in such cases.
4
5
Causes of Non- Linearity
• Drug Absorption
– When absorption is solubility or dissolution is rate limited eg.
Griseofulvin
– When absorption involves carrier mediated transport system eg.
Riboflavin
– Hepatic metabolism attains saturation eg. Propranolol,Verapamil
• Drug Distribution
– Saturation of binding sites on plasma protiens eg. Phenylbutazone,
Naproxen
– Saturation of tissue binding site eg. Thiopental
6
• Drug Metabolism
– Capacity limited metabolism due to enzyme and
cofactorsaturation. eg. Phenytoin, alcohol.
– Enzyme induction eg. Carbamazepine
• Drug Excretion
– Active tubular secretion eg. Penicilin G
– Active tubular reabsorption eg. Glucose, water soluble
vitamins
– Change in urine pH, nephrotoxicity & saturation of binding
sites
7
CONDITIONS WHEN DRUG FOLLOWS
NON LINEAR PHARMACOKINETICS3
• Plasma concentration time profile is not linear.
• AUC is not proportional to administered dose after
administration of single dose.
• Steady state plasma concentration is not proportional to
administered dose during multiple drug administrations.
• Estimated PK parameters such as half- life and total body
clearance are different after administration of different doses.
8
SATURABLE ENZYMATIC ELIMINATION
PROCESS2
• MICHAELIS MENTEN Equation –
- dc/dt = Vmax C/ Km +C----------(1)
Where,
-dc/dt = rate of decline of drug conc.with time
Vmax = theoretical maximum rate of the process
Km = Michaelis constant
9
10
Now t
11
2) When Km >> C ,
Here Km + C = Km and the equation (1)
becomes ,
- dc/ dt = VmaxC/Km
12
DRUG ELIMINATION BY CAPACITY LIMITED
PK
(Estimation of Vmax & Km )2
• Parameters of capacity limited processes like metabolism,
renal tubular secretion & billiary excretion defined by
assuming one compartment kinetics for the drug & that
elimination involves only a single capacity limited process.
• Parameters Km & V max can be assessed from plasma
concentration time data collected after I.V. bolus
administration of drug with non linear elimination
characteristics.
13
Now rewriting Michaelis Menten equation,
-dc/dt =VmaxC/Km+c
Integrating above eqn to log base 10 yields ,
Logc=logCo+(Co-C)/2.303Km –(Vmax)/2.303Km
….. (2)
A semilog plot of C versus t yields a curve with a terminal linear
portion having slope -Vmax/2.303Km and when back extra
plotted to time zero gives Y intercept log Co
The equation that deascribes this line is
log C = log Co – Vmax/2.303 Km ….. (3)
14
Fig.-semilog plot of A drug given as i.v. Bolus With non linear
elimination& that fits one compartmet kinetics.
15
At low plasma concentration equation (2) & (3) are identical.
Equating the two and simplifying further we get
(Co- C) / 2.303 Km = log Co / Co
From above equation we can calculate Km and Vmax can be
obtained by substituting the value of Km in the slope value.
16
17
Mixed Drug Elimination1
• Drugs may be metabolized to several different metabolites by
parallel pathways.
• At low drug doses corresponding to low drug concentrations at the
site of the biotransformation enzymes, the rates of formation of
metabolites are first order.
• However, with higher doses of drug, more drug is absorbed and
higher drug concentrations are presented to the biotransformation
enzymes.
• At higher drug concentrations, the enzyme involved in metabolite
formation may become saturated, and the rate of metabolite
formation becomes nonlinear and approaches zero order. Ex.
Sodium salicylate 18
The equation that describes a drug that is eliminated
by both first-order and Michaelis–Menten kinetics
after IV bolus injection is given by
where k is the first-order rate constant representing the
sum of all first-order elimination processes,
(V’maxCp/Km+Cp) = saturable process.
V'max is simply V max expressed as concentration by
dividing by V D.
-dCp/dt= kCp+(V’maxCp/Km+Cp)
19
Time-dependent pharmacokinetics1
• Time-dependent pharmacokinetics generally refers to a
noncyclical change in the drug absorption or drug
elimination rate process over a period of time.
• Time-dependent pharmacokinetics leads to nonlinear
pharmacokinetics. Unlike dose-dependent
pharmacokinetics, which involves a change in the rate
process when the dose is changed.
20
21
Conclusion
• Non linear pharmacokinetic is observed when absorption
,distribution or elimination processes can be saturated at a
high drug concentration.
• Drugs that behave non linearly within the therapeutic range
(Ex.-Phenytoin shows saturable metabolism ) yields less
predictable results in drug therapy & possesses greater
potential in precipitating a toxic effects.
22
References
1) Shargel Leon, Susanna Wu-pong, Andrew B.C.YU, “Applied
Biopharmaceutics & Pharmacokinetics", 5thedition2005;
published by Mc Graw Hill page no-219-241
2) Biopharmaceutics and pharmacokinetics. D.M Brahmankar and
Sunil. B .Jaiswal, ,1st edition page no-305-313
3) Basic pharmacokinetics M.A.Hedaya CRC press first indian
reprint page no-169-180
23
24

More Related Content

What's hot

Urinaryexcreation studies
Urinaryexcreation studiesUrinaryexcreation studies
Urinaryexcreation studiesSonam Gandhi
 
Methods of enhancing bioavailability of drugs
Methods of enhancing bioavailability of drugsMethods of enhancing bioavailability of drugs
Methods of enhancing bioavailability of drugsDebasish Ghadei
 
Michaelis menten kinetics Nonlinear Pharmacokinetics
Michaelis menten kinetics Nonlinear PharmacokineticsMichaelis menten kinetics Nonlinear Pharmacokinetics
Michaelis menten kinetics Nonlinear PharmacokineticsSyed Umar Farooq
 
Methods For Assesment Of Bioavailability
Methods For Assesment Of Bioavailability Methods For Assesment Of Bioavailability
Methods For Assesment Of Bioavailability Anindya Jana
 
Basic pharmacokinetics and compartment modelling
Basic pharmacokinetics  and compartment modellingBasic pharmacokinetics  and compartment modelling
Basic pharmacokinetics and compartment modellingPriyankaDabirBharadk
 
Two compartment model
Two compartment modelTwo compartment model
Two compartment modelRooma Khalid
 
ONE COMPARTMENT OPEN MODEL I.V BOLUS (Contact me: dr.m.bharathkumar@gmail.com)
ONE COMPARTMENT OPEN MODEL I.V BOLUS (Contact me: dr.m.bharathkumar@gmail.com)ONE COMPARTMENT OPEN MODEL I.V BOLUS (Contact me: dr.m.bharathkumar@gmail.com)
ONE COMPARTMENT OPEN MODEL I.V BOLUS (Contact me: dr.m.bharathkumar@gmail.com)DR. METI.BHARATH KUMAR
 
Multi compartment models
Multi compartment models Multi compartment models
Multi compartment models SafalataJain
 
Compartment modeling
Compartment modelingCompartment modeling
Compartment modelingSHILPI BISWAS
 
Gastrointestinal absorption of drugs
Gastrointestinal absorption of drugsGastrointestinal absorption of drugs
Gastrointestinal absorption of drugsSiddu K M
 
Two compartment model iv bolus muju
Two compartment model iv bolus mujuTwo compartment model iv bolus muju
Two compartment model iv bolus mujuHirepravin
 
Pharmacokinetics / Biopharmaceutics - One compartment model IV bolus
Pharmacokinetics / Biopharmaceutics - One compartment model IV bolusPharmacokinetics / Biopharmaceutics - One compartment model IV bolus
Pharmacokinetics / Biopharmaceutics - One compartment model IV bolusAreej Abu Hanieh
 
Methods of Assessing Bioavailability
Methods of Assessing BioavailabilityMethods of Assessing Bioavailability
Methods of Assessing BioavailabilityDibrugarh University
 
Protein drug binding
Protein drug bindingProtein drug binding
Protein drug bindingSnehal Patel
 
Causes of Non linear pharmacokinetics
Causes of Non linear pharmacokineticsCauses of Non linear pharmacokinetics
Causes of Non linear pharmacokineticsSnehal Patel
 

What's hot (20)

Urinaryexcreation studies
Urinaryexcreation studiesUrinaryexcreation studies
Urinaryexcreation studies
 
Pharmacokinetic models
Pharmacokinetic  modelsPharmacokinetic  models
Pharmacokinetic models
 
Methods of enhancing bioavailability of drugs
Methods of enhancing bioavailability of drugsMethods of enhancing bioavailability of drugs
Methods of enhancing bioavailability of drugs
 
In-Vivo In-Vitro Correlation
In-Vivo In-Vitro CorrelationIn-Vivo In-Vitro Correlation
In-Vivo In-Vitro Correlation
 
Michaelis menten kinetics Nonlinear Pharmacokinetics
Michaelis menten kinetics Nonlinear PharmacokineticsMichaelis menten kinetics Nonlinear Pharmacokinetics
Michaelis menten kinetics Nonlinear Pharmacokinetics
 
Methods For Assesment Of Bioavailability
Methods For Assesment Of Bioavailability Methods For Assesment Of Bioavailability
Methods For Assesment Of Bioavailability
 
Basic pharmacokinetics and compartment modelling
Basic pharmacokinetics  and compartment modellingBasic pharmacokinetics  and compartment modelling
Basic pharmacokinetics and compartment modelling
 
Two compartment model
Two compartment modelTwo compartment model
Two compartment model
 
Nonlinear Pharmacokinetics
Nonlinear PharmacokineticsNonlinear Pharmacokinetics
Nonlinear Pharmacokinetics
 
ONE COMPARTMENT OPEN MODEL I.V BOLUS (Contact me: dr.m.bharathkumar@gmail.com)
ONE COMPARTMENT OPEN MODEL I.V BOLUS (Contact me: dr.m.bharathkumar@gmail.com)ONE COMPARTMENT OPEN MODEL I.V BOLUS (Contact me: dr.m.bharathkumar@gmail.com)
ONE COMPARTMENT OPEN MODEL I.V BOLUS (Contact me: dr.m.bharathkumar@gmail.com)
 
PHARMACOKINETIC MODELS
PHARMACOKINETIC MODELSPHARMACOKINETIC MODELS
PHARMACOKINETIC MODELS
 
Multi compartment models
Multi compartment models Multi compartment models
Multi compartment models
 
Compartment modeling
Compartment modelingCompartment modeling
Compartment modeling
 
Gastrointestinal absorption of drugs
Gastrointestinal absorption of drugsGastrointestinal absorption of drugs
Gastrointestinal absorption of drugs
 
Two compartment model iv bolus muju
Two compartment model iv bolus mujuTwo compartment model iv bolus muju
Two compartment model iv bolus muju
 
Pharmacokinetics / Biopharmaceutics - One compartment model IV bolus
Pharmacokinetics / Biopharmaceutics - One compartment model IV bolusPharmacokinetics / Biopharmaceutics - One compartment model IV bolus
Pharmacokinetics / Biopharmaceutics - One compartment model IV bolus
 
Methods of Assessing Bioavailability
Methods of Assessing BioavailabilityMethods of Assessing Bioavailability
Methods of Assessing Bioavailability
 
Protein drug binding
Protein drug bindingProtein drug binding
Protein drug binding
 
Causes of Non linear pharmacokinetics
Causes of Non linear pharmacokineticsCauses of Non linear pharmacokinetics
Causes of Non linear pharmacokinetics
 
Non compartmental modelling
Non compartmental modellingNon compartmental modelling
Non compartmental modelling
 

Similar to Non linear kinetics

Non linear pharmacokinetics
Non linear pharmacokineticsNon linear pharmacokinetics
Non linear pharmacokineticsShashi Yadav
 
NONLINEAR PHARMACOKINETICS_ppt.pdf
NONLINEAR PHARMACOKINETICS_ppt.pdfNONLINEAR PHARMACOKINETICS_ppt.pdf
NONLINEAR PHARMACOKINETICS_ppt.pdfKirti Goel
 
Biopharmaceutics Non linear pharmacokinetics
Biopharmaceutics Non linear pharmacokineticsBiopharmaceutics Non linear pharmacokinetics
Biopharmaceutics Non linear pharmacokineticsshortsmotivation87
 
Concept of nonlinear pharmacokinetic
Concept of nonlinear pharmacokineticConcept of nonlinear pharmacokinetic
Concept of nonlinear pharmacokinetickavita bahmani
 
Nonlinear pharmacokinetic
Nonlinear pharmacokineticNonlinear pharmacokinetic
Nonlinear pharmacokineticbuner12345
 
BPharma-6Sem-Biopharmaceutics & Pharmacokinetics.pdf
BPharma-6Sem-Biopharmaceutics & Pharmacokinetics.pdfBPharma-6Sem-Biopharmaceutics & Pharmacokinetics.pdf
BPharma-6Sem-Biopharmaceutics & Pharmacokinetics.pdfKaamDhenu
 
Therapeutic drug monitoring LECTURE 2.pptx pharmaceutical sciences
Therapeutic drug monitoring LECTURE 2.pptx pharmaceutical sciencesTherapeutic drug monitoring LECTURE 2.pptx pharmaceutical sciences
Therapeutic drug monitoring LECTURE 2.pptx pharmaceutical scienceskhalafpharm
 
kinetics (Lec 2).pptx
kinetics (Lec 2).pptxkinetics (Lec 2).pptx
kinetics (Lec 2).pptxHebaYassin10
 
Non linear pharmacokinetics.
Non linear pharmacokinetics.Non linear pharmacokinetics.
Non linear pharmacokinetics.jatin singla
 
kineticsofstabilityanstabilitytesting-200327002128.pdf
kineticsofstabilityanstabilitytesting-200327002128.pdfkineticsofstabilityanstabilitytesting-200327002128.pdf
kineticsofstabilityanstabilitytesting-200327002128.pdffarsiya
 
Kinetics of stability and stability testing
Kinetics of stability and stability testingKinetics of stability and stability testing
Kinetics of stability and stability testingAnkit Malik
 
Non linear Pharmacokinetics 2
Non linear Pharmacokinetics 2Non linear Pharmacokinetics 2
Non linear Pharmacokinetics 2Areej Abu Hanieh
 
Basic concepts of pharmacokinetics
Basic concepts of pharmacokineticsBasic concepts of pharmacokinetics
Basic concepts of pharmacokineticsAnand Addagalla
 
Basic concepts of pharmacokinetics
Basic concepts of pharmacokineticsBasic concepts of pharmacokinetics
Basic concepts of pharmacokineticsAnand Addagalla
 
METHOD OF RESIDUALS
METHOD OF RESIDUALSMETHOD OF RESIDUALS
METHOD OF RESIDUALSDivya Pushp
 
Pharmacokinetics / Biopharmaceutics - drug absorption
Pharmacokinetics / Biopharmaceutics - drug absorptionPharmacokinetics / Biopharmaceutics - drug absorption
Pharmacokinetics / Biopharmaceutics - drug absorptionAreej Abu Hanieh
 
Basic Pharmacokinetics & Compartments Modelling.pdf
Basic Pharmacokinetics & Compartments Modelling.pdfBasic Pharmacokinetics & Compartments Modelling.pdf
Basic Pharmacokinetics & Compartments Modelling.pdfAshwin Saxena
 
Michaelis-menten kinetics
Michaelis-menten kineticsMichaelis-menten kinetics
Michaelis-menten kineticsMunawar Ali
 

Similar to Non linear kinetics (20)

Non linear pharmacokinetics
Non linear pharmacokineticsNon linear pharmacokinetics
Non linear pharmacokinetics
 
NONLINEAR PHARMACOKINETICS_ppt.pdf
NONLINEAR PHARMACOKINETICS_ppt.pdfNONLINEAR PHARMACOKINETICS_ppt.pdf
NONLINEAR PHARMACOKINETICS_ppt.pdf
 
Biopharmaceutics Non linear pharmacokinetics
Biopharmaceutics Non linear pharmacokineticsBiopharmaceutics Non linear pharmacokinetics
Biopharmaceutics Non linear pharmacokinetics
 
Concept of nonlinear pharmacokinetic
Concept of nonlinear pharmacokineticConcept of nonlinear pharmacokinetic
Concept of nonlinear pharmacokinetic
 
Nonlinear pharmacokinetic
Nonlinear pharmacokineticNonlinear pharmacokinetic
Nonlinear pharmacokinetic
 
BPharma-6Sem-Biopharmaceutics & Pharmacokinetics.pdf
BPharma-6Sem-Biopharmaceutics & Pharmacokinetics.pdfBPharma-6Sem-Biopharmaceutics & Pharmacokinetics.pdf
BPharma-6Sem-Biopharmaceutics & Pharmacokinetics.pdf
 
Therapeutic drug monitoring LECTURE 2.pptx pharmaceutical sciences
Therapeutic drug monitoring LECTURE 2.pptx pharmaceutical sciencesTherapeutic drug monitoring LECTURE 2.pptx pharmaceutical sciences
Therapeutic drug monitoring LECTURE 2.pptx pharmaceutical sciences
 
kinetics (Lec 2).pptx
kinetics (Lec 2).pptxkinetics (Lec 2).pptx
kinetics (Lec 2).pptx
 
Non linear pharmacokinetics.
Non linear pharmacokinetics.Non linear pharmacokinetics.
Non linear pharmacokinetics.
 
kineticsofstabilityanstabilitytesting-200327002128.pdf
kineticsofstabilityanstabilitytesting-200327002128.pdfkineticsofstabilityanstabilitytesting-200327002128.pdf
kineticsofstabilityanstabilitytesting-200327002128.pdf
 
Kinetics of stability and stability testing
Kinetics of stability and stability testingKinetics of stability and stability testing
Kinetics of stability and stability testing
 
Non linear Pharmacokinetics 2
Non linear Pharmacokinetics 2Non linear Pharmacokinetics 2
Non linear Pharmacokinetics 2
 
Basic concepts of pharmacokinetics
Basic concepts of pharmacokineticsBasic concepts of pharmacokinetics
Basic concepts of pharmacokinetics
 
Basic concepts of pharmacokinetics
Basic concepts of pharmacokineticsBasic concepts of pharmacokinetics
Basic concepts of pharmacokinetics
 
Abp08.pptx
Abp08.pptxAbp08.pptx
Abp08.pptx
 
METHOD OF RESIDUALS
METHOD OF RESIDUALSMETHOD OF RESIDUALS
METHOD OF RESIDUALS
 
Pharmacokinetics / Biopharmaceutics - drug absorption
Pharmacokinetics / Biopharmaceutics - drug absorptionPharmacokinetics / Biopharmaceutics - drug absorption
Pharmacokinetics / Biopharmaceutics - drug absorption
 
Basic Pharmacokinetics & Compartments Modelling.pdf
Basic Pharmacokinetics & Compartments Modelling.pdfBasic Pharmacokinetics & Compartments Modelling.pdf
Basic Pharmacokinetics & Compartments Modelling.pdf
 
Saturation kinetics
Saturation kineticsSaturation kinetics
Saturation kinetics
 
Michaelis-menten kinetics
Michaelis-menten kineticsMichaelis-menten kinetics
Michaelis-menten kinetics
 

More from Suvarta Maru

case study - Urinary tract infection with diabetes mellitus
case study - Urinary tract infection with  diabetes mellitus case study - Urinary tract infection with  diabetes mellitus
case study - Urinary tract infection with diabetes mellitus Suvarta Maru
 
WORLD HEALTH ORGANIZATION ( WHO )
WORLD HEALTH ORGANIZATION ( WHO )WORLD HEALTH ORGANIZATION ( WHO )
WORLD HEALTH ORGANIZATION ( WHO )Suvarta Maru
 
Various approachesto drug discovery
Various approachesto drug discoveryVarious approachesto drug discovery
Various approachesto drug discoverySuvarta Maru
 
Schedules of drugs
Schedules of drugsSchedules of drugs
Schedules of drugsSuvarta Maru
 
Quinolone antibacterials
Quinolone antibacterialsQuinolone antibacterials
Quinolone antibacterialsSuvarta Maru
 
Protein binding of drug
Protein binding of drugProtein binding of drug
Protein binding of drugSuvarta Maru
 
Preclinical trials
Preclinical trialsPreclinical trials
Preclinical trialsSuvarta Maru
 
Poison AND treatment
Poison AND treatmentPoison AND treatment
Poison AND treatmentSuvarta Maru
 
Pharmacovigilance STUDY
Pharmacovigilance STUDYPharmacovigilance STUDY
Pharmacovigilance STUDYSuvarta Maru
 
Pharmacoeconomics STUDY
Pharmacoeconomics STUDYPharmacoeconomics STUDY
Pharmacoeconomics STUDYSuvarta Maru
 
OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)
OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)
OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)Suvarta Maru
 
NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)
NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)
NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)Suvarta Maru
 

More from Suvarta Maru (20)

case study - Urinary tract infection with diabetes mellitus
case study - Urinary tract infection with  diabetes mellitus case study - Urinary tract infection with  diabetes mellitus
case study - Urinary tract infection with diabetes mellitus
 
WORLD HEALTH ORGANIZATION ( WHO )
WORLD HEALTH ORGANIZATION ( WHO )WORLD HEALTH ORGANIZATION ( WHO )
WORLD HEALTH ORGANIZATION ( WHO )
 
Various approachesto drug discovery
Various approachesto drug discoveryVarious approachesto drug discovery
Various approachesto drug discovery
 
USFDA & WHO
USFDA & WHOUSFDA & WHO
USFDA & WHO
 
US FDA
US FDA US FDA
US FDA
 
Toxicity slides
Toxicity slidesToxicity slides
Toxicity slides
 
TGA & MHRA
TGA & MHRATGA & MHRA
TGA & MHRA
 
Thermal analysis
Thermal analysisThermal analysis
Thermal analysis
 
Stroke study
Stroke studyStroke study
Stroke study
 
Schedules of drugs
Schedules of drugsSchedules of drugs
Schedules of drugs
 
Schedule m
Schedule  m Schedule  m
Schedule m
 
Quinolone antibacterials
Quinolone antibacterialsQuinolone antibacterials
Quinolone antibacterials
 
Protein binding of drug
Protein binding of drugProtein binding of drug
Protein binding of drug
 
Preclinical trials
Preclinical trialsPreclinical trials
Preclinical trials
 
Poison AND treatment
Poison AND treatmentPoison AND treatment
Poison AND treatment
 
Pharmacovigilance STUDY
Pharmacovigilance STUDYPharmacovigilance STUDY
Pharmacovigilance STUDY
 
Pharmacoeconomics STUDY
Pharmacoeconomics STUDYPharmacoeconomics STUDY
Pharmacoeconomics STUDY
 
OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)
OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)
OPTICAL ROTATORY DISPERSION & CIRCULAR DICHORISM(ORD CD)
 
NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)
NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)
NON STEROIDAL ANTI INFLAMMTORY DRUGS ( NSAID'S)
 
New drug approval
New drug approvalNew drug approval
New drug approval
 

Recently uploaded

Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsTechSoup
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsMebane Rash
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...Poonam Aher Patil
 
Google Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxGoogle Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxDr. Sarita Anand
 
Single or Multiple melodic lines structure
Single or Multiple melodic lines structureSingle or Multiple melodic lines structure
Single or Multiple melodic lines structuredhanjurrannsibayan2
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...Nguyen Thanh Tu Collection
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxCeline George
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxRamakrishna Reddy Bijjam
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxheathfieldcps1
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfDr Vijay Vishwakarma
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.pptRamjanShidvankar
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfAdmir Softic
 
Wellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxWellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxJisc
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and ModificationsMJDuyan
 
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...Nguyen Thanh Tu Collection
 
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxAmanpreet Kaur
 
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Pooja Bhuva
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxDr. Ravikiran H M Gowda
 

Recently uploaded (20)

Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
Google Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptxGoogle Gemini An AI Revolution in Education.pptx
Google Gemini An AI Revolution in Education.pptx
 
Single or Multiple melodic lines structure
Single or Multiple melodic lines structureSingle or Multiple melodic lines structure
Single or Multiple melodic lines structure
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
How to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptxHow to setup Pycharm environment for Odoo 17.pptx
How to setup Pycharm environment for Odoo 17.pptx
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
Key note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdfKey note speaker Neum_Admir Softic_ENG.pdf
Key note speaker Neum_Admir Softic_ENG.pdf
 
Wellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxWellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptx
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
Spatium Project Simulation student brief
Spatium Project Simulation student briefSpatium Project Simulation student brief
Spatium Project Simulation student brief
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
 
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptxSKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
SKILL OF INTRODUCING THE LESSON MICRO SKILLS.pptx
 
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptx
 

Non linear kinetics

  • 2. Contents Introduction Definition Saturable enzymatic elimination process Drug elimination by capacity limited pk Mixed drug elimination Time dependent PK Conclusion References 2
  • 3. LINEAR PHARMACOKINETICS • linear kinetics : In most cases, at therapeutic doses, the change in the amount of drug in the body or change in plasma concentration due to ADME is directly proportional to its dose, whether single or multiple dose. In such situations, the rate process are said to follow first order or linear kinetics. • Plot on semilog paper C vs t for different doses, when corrected for dose administered, are super impossible. This is called as principle of superposition. • It defines the relationship between the dose & the time course of drug concentration in the body.. 3
  • 4. NON LINEAR PHARMACOKINETICS2 • Synonyms: Capacity limited Kinetics, Mixed order Kinetics (Dose Dependent Kinetics) ,Nonlinear • Why it is known as Mixed order kinetics? In some cases the kinetics of PK process changes from 1st order to zero order with increase in dose or chronic medication. So mixture of both 1st and zero order observed in such cases. 4
  • 5. 5
  • 6. Causes of Non- Linearity • Drug Absorption – When absorption is solubility or dissolution is rate limited eg. Griseofulvin – When absorption involves carrier mediated transport system eg. Riboflavin – Hepatic metabolism attains saturation eg. Propranolol,Verapamil • Drug Distribution – Saturation of binding sites on plasma protiens eg. Phenylbutazone, Naproxen – Saturation of tissue binding site eg. Thiopental 6
  • 7. • Drug Metabolism – Capacity limited metabolism due to enzyme and cofactorsaturation. eg. Phenytoin, alcohol. – Enzyme induction eg. Carbamazepine • Drug Excretion – Active tubular secretion eg. Penicilin G – Active tubular reabsorption eg. Glucose, water soluble vitamins – Change in urine pH, nephrotoxicity & saturation of binding sites 7
  • 8. CONDITIONS WHEN DRUG FOLLOWS NON LINEAR PHARMACOKINETICS3 • Plasma concentration time profile is not linear. • AUC is not proportional to administered dose after administration of single dose. • Steady state plasma concentration is not proportional to administered dose during multiple drug administrations. • Estimated PK parameters such as half- life and total body clearance are different after administration of different doses. 8
  • 9. SATURABLE ENZYMATIC ELIMINATION PROCESS2 • MICHAELIS MENTEN Equation – - dc/dt = Vmax C/ Km +C----------(1) Where, -dc/dt = rate of decline of drug conc.with time Vmax = theoretical maximum rate of the process Km = Michaelis constant 9
  • 10. 10
  • 12. 2) When Km >> C , Here Km + C = Km and the equation (1) becomes , - dc/ dt = VmaxC/Km 12
  • 13. DRUG ELIMINATION BY CAPACITY LIMITED PK (Estimation of Vmax & Km )2 • Parameters of capacity limited processes like metabolism, renal tubular secretion & billiary excretion defined by assuming one compartment kinetics for the drug & that elimination involves only a single capacity limited process. • Parameters Km & V max can be assessed from plasma concentration time data collected after I.V. bolus administration of drug with non linear elimination characteristics. 13
  • 14. Now rewriting Michaelis Menten equation, -dc/dt =VmaxC/Km+c Integrating above eqn to log base 10 yields , Logc=logCo+(Co-C)/2.303Km –(Vmax)/2.303Km ….. (2) A semilog plot of C versus t yields a curve with a terminal linear portion having slope -Vmax/2.303Km and when back extra plotted to time zero gives Y intercept log Co The equation that deascribes this line is log C = log Co – Vmax/2.303 Km ….. (3) 14
  • 15. Fig.-semilog plot of A drug given as i.v. Bolus With non linear elimination& that fits one compartmet kinetics. 15
  • 16. At low plasma concentration equation (2) & (3) are identical. Equating the two and simplifying further we get (Co- C) / 2.303 Km = log Co / Co From above equation we can calculate Km and Vmax can be obtained by substituting the value of Km in the slope value. 16
  • 17. 17
  • 18. Mixed Drug Elimination1 • Drugs may be metabolized to several different metabolites by parallel pathways. • At low drug doses corresponding to low drug concentrations at the site of the biotransformation enzymes, the rates of formation of metabolites are first order. • However, with higher doses of drug, more drug is absorbed and higher drug concentrations are presented to the biotransformation enzymes. • At higher drug concentrations, the enzyme involved in metabolite formation may become saturated, and the rate of metabolite formation becomes nonlinear and approaches zero order. Ex. Sodium salicylate 18
  • 19. The equation that describes a drug that is eliminated by both first-order and Michaelis–Menten kinetics after IV bolus injection is given by where k is the first-order rate constant representing the sum of all first-order elimination processes, (V’maxCp/Km+Cp) = saturable process. V'max is simply V max expressed as concentration by dividing by V D. -dCp/dt= kCp+(V’maxCp/Km+Cp) 19
  • 20. Time-dependent pharmacokinetics1 • Time-dependent pharmacokinetics generally refers to a noncyclical change in the drug absorption or drug elimination rate process over a period of time. • Time-dependent pharmacokinetics leads to nonlinear pharmacokinetics. Unlike dose-dependent pharmacokinetics, which involves a change in the rate process when the dose is changed. 20
  • 21. 21
  • 22. Conclusion • Non linear pharmacokinetic is observed when absorption ,distribution or elimination processes can be saturated at a high drug concentration. • Drugs that behave non linearly within the therapeutic range (Ex.-Phenytoin shows saturable metabolism ) yields less predictable results in drug therapy & possesses greater potential in precipitating a toxic effects. 22
  • 23. References 1) Shargel Leon, Susanna Wu-pong, Andrew B.C.YU, “Applied Biopharmaceutics & Pharmacokinetics", 5thedition2005; published by Mc Graw Hill page no-219-241 2) Biopharmaceutics and pharmacokinetics. D.M Brahmankar and Sunil. B .Jaiswal, ,1st edition page no-305-313 3) Basic pharmacokinetics M.A.Hedaya CRC press first indian reprint page no-169-180 23
  • 24. 24